Business Wire

4MOVING-BIOTECH

Share
4Moving Biotech welcomes Luc Boblet as Chief Executive Officer to lead next phase of growth

4Moving Biotech (4MB), a clinical-stage subsidiary of 4P-Pharma specializing in immuno-inflammation and osteoarthritis, is pleased to announce the appointment of Luc Boblet as Chief Executive Officer. The company, having successfully completed its Phase I clinical trial and a preparatory in silico Phase 2 analysis, looks to Luc Boblet's seasoned expertise in biotech entrepreneurship and strategic development to guide the forthcoming stages of clinical proof of concept and early market access.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240701233556/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Luc Boblet, CEO OF 4Moving Biotech (Photo: Business Wire)

Luc Boblet, a biotech entrepreneur with two decades of experience, joins 4MB following his tenure at Egle Therapeutics, where his leadership was essential in advancing novel immunotherapies and securing a robust Series A funding backed by a big pharma strategic alliance. His previous roles included founding and leading companies such as H-IMMUNE - acquired by HiFiBIO - and Pathoquest, where he excelled in driving innovation, closing fundraising and forging strategic partnerships as instrumental catalyst of growth.

"Luc's appointment comes at a turning point for 4Moving Biotech as we have concluded a milestone Phase I trial for our leading drug candidate and are advancing strategic discussions with the FDA, toward potential accelerated approval" said Revital Rattenbach, founder and CEO of 4P-Pharma and co-founder of 4Moving. "His track record in steering biotech ventures and his strategic approach to partnerships will be invaluable as we advance our clinical programs and explore opportunities for pharma co-development and partnership."

As CEO of 4Moving Biotech, Luc Boblet's immediate focus will be on overseeing the design and implementation of the development strategy for the upcoming Phase II clinical trials, as well as cultivating partnerships that align with the company's vision for growth and patient access to innovative treatments.

Luc Boblet, CEO of 4Moving Biotech said: "The opportunity to lead 4Moving Biotech at this juncture is one that is aligned with my commitment to bringing pioneering therapies for untreated severe diseases. The company's progress in drug development and the potential to significantly improve patient outcomes in osteoarthritis is a strong foundation for future success. I am looking forward to applying my experience in corporate strategy business development to deliver our value proposal and establish meaningful partnerships."

About 4Moving Biotech

4Moving Biotech, a subsidiary of 4P-Pharma, is dedicated to developing advanced first in class therapies in the field of immuno-inflammation and osteoarthritis. With a commitment to improving patient care, 4MB is actively engaged in the clinical development of novel treatments poised to enhance quality of life for patients worldwide.

Biography of Luc Boblet, CEO of 4Moving Biotech.

Luc Boblet is a serial biotech entrepreneur with 20 years of experience in entrepreneurship, business development, corporate finance and early drug development. Luc is coming from Egle Therapeutics, spin out of Institut Curie dedicated to developing novel Regulatory T-cells based immunotherapies for oncology and autoimmune diseases, he has co-founded in early 2020. As a founding CEO, he built Egle Tx with a vision to become a game changer in the field of Tregs immunomodulation catalyzed by strategic alliance with Takeda Pharmaceutical and backed by 45M€ Series A from a high-quality syndicate of renowned international investors. Before creating Egle Tx, Luc co-founded and ran H-IMMUNE, start-up spun out of French Nuclear Agency (CEA), developing novel anti-check-point immunotherapies against T-effector and Tregs for oncology. He paved H-IMMUNE corporate path through partnerships with Pierre Fabre Laboratories and Norther Biologics and have exited H-IMMUNE through an acquisition by HiFiBIO in 2018. Before co-founding H-IMMUNE, Luc co-founded and ran Pathoquest, a start-up company spun out of Institute Pasteur, which develops disruptive unbiased NGS-based diagnostics in the field of infectious diseases. Under his guidance, Pathoquest raised two VC-backed rounds of financing, closed strategic collaborations and corporate partnerships with leading pharma companies (CERBA Laboratories and Covance), and launched several clinicals trials in France and the U.S.
From 2011 to 2015, he served on the board of directors of the BioAster Technological Research Institute.
He started his career in technology transfer, consulting in finance and business development for toxicogenomics R&D. Luc Boblet holds a biotech engineering degree, master’s degree in Virology and has been trained as a PhD in Virology from University Paris VII.

About 4Moving Biotech

Incorporated in mid 2020 as a spin-off of 4P-Pharma, 4Moving Biotech is a clinical stage biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD). Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis. The company is headquartered at the Pasteur Institute in Lille, France.

Website: https://www.4movingbiotech.com/
LinkedIn: https://fr.linkedin.com/company/4moving-biotech
X: https://twitter.com/4Moving_Biotech

The only version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240701233556/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Titan Telecoms deploys 800G flexible spectrum between Sydney and Melbourne with Adtran’s FSP 3000 TeraFlex™15.1.2025 14:15:00 CET | Press release

News summary: Resilient, high-speed connectivity is needed across Southeast Australia to support enterprise cloud services and data-intensive applications Multi-vendor network delivers high-capacity adaptive bandwidth over a long-haul link using Adtran terminal and Ciena OLS Dynamic spectrum allocation and optimized fiber utilization enable cost-effective, high-speed data transport across long distances Adtran announced today that Titan Telecomsis using its FSP 3000 TeraFlex™ CoreChannel™ technology to transport 800Gbit/s flexible spectrum services over a 963km backbone link between Sydney and Melbourne. This multi-vendor network addresses high-capacity connectivity needs by enabling commercial spectrum service offerings across Southeast Australia. The new service utilizes Adtran’s FSP 3000 TeraFlex™ CoreChannel™ optical terminal to enable dynamic bandwidth allocation and optimized fiber utilization. Its success sets a new standard for flexible spectrum transport and future high-capaci

The smarter E Europe: Bidirectional Charging Saves Billions15.1.2025 14:00:00 CET | Press release

Electric cars equipped with bidirectional charging technology can store electricity and feed it back into the grid when needed. A new study by Transport & Environment (T&E) shows that this could save billions by optimizing the use of generation capacity, reducing curtailment, and lowering fuel consumption. Bidirectional charging (BiDi) could thus achieve a technological and economic breakthrough in Europe but it requires clear regulatory framework conditions. Without these, the potential will remain untapped. In response to these developments, Europe’s largest alliance of energy industry exhibitions, The smarter E Europe, is dedicating a special exhibit to highlight the opportunities and challenges for the mobility and energy industries. The event will take place from May 7–9, 2025, at Messe München. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115069203/en/ The interplay of mobility and renewable energy: The smarter E

Arthur D. Little Blue Shift Report Explores Transformative Impact of AI on Research, Development, and Innovation15.1.2025 13:00:00 CET | Press release

AI has started to power all steps of research, development, and innovation (R&D&I), including those that require creativity, working alongside and augmenting humans, with its use increasing rapidly. However, while it is already delivering major productivity gains in specific areas or sectors its widespread integration into R&D&I processes is still relatively immature, and it faces a range of challenges around technology, economics, regulation, and societal acceptability. Irrespective of these challenges, six no-regret strategic actions should be undertaken today. These are the headline findings of Eureka! on Steroids: AI-driven research, development, and innovation, a new report published today byArthur D. Little (ADL)’s Blue Shift Institute. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115868503/en/ In this new study, Arthur D. Little explores the current state of AI in research, development, and innovation. (Photo: Bu

Europastry and Blue Yonder Team Up To Strategically Drive Efficiency, Sustainability and Customer Satisfaction15.1.2025 10:00:00 CET | Press release

Global bakery leader implements Blue Yonder transportation management solutions supported by BlueGistics to optimize supply chain operations across Europe Delivering frozen bakery products presents several challenges that can impact the efficiency, profitability and sustainability of the supply chain. To address these challenges, Europastry, a world leader in the frozen bakery industry, has selected Blue Yonder’s transportation management solutions to evolve its supply processes and optimize its logistics operations. The transformational project was deployed by BlueGistics, a Blue Yonder partner and worldwide consulting company specializing in the implementation of Transportation Management Systems. With an ever-growing distribution network spanning more than 80 countries, Europastry sought to increase efficiency in its transportation processes, reduce costs, and continue delivering its wide range of bakery products efficiently. Blue Yonder’s transportation management solutions provide

Tax Systems Launches AI-powered, SaaS Solution for Global Pillar Two Compliance and Reporting15.1.2025 09:00:00 CET | Press release

Secure, scalable software that ensures organisations are prepared for the challenges of OECD Pillar Two rules now and in the future Tax Systems, the global multi-tax compliance SaaS provider, has today announced the availability of Pillar2, an intuitive solution to de-risk and simplify compliance with the OECD’s global Pillar Two tax rules. Designed for organisations operating across multiple jurisdictions - Pillar2 will save businesses valuable time and reduce the risk of errors, so they can cost effectively operationalise Pillar Two reporting and comply with confidence. Pillar2 integrates seamlessly with the provisioning and country-by-country reporting applications on TaxSuite - Tax Systems’ modular platform for international tax compliance. This means organisations can upload information once and re-use it as a single source of truth for their tax compliance data - helping to ensure consistency and accuracy across the tax reporting cycle and strengthen tax control frameworks. The s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye